共 50 条
- [1] A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neckJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Thomas, Jacob StephenBruce, Justine YangLi, ZujunLorch, Jochen H.Phillips, TanyanikaVillaflor, VictoriaRuel, ChristopherPalmer, JoycelynneGutkind, J. SilvioVillalona-Calero, Miguel AngelColevas, Alexander Dimitrios
- [2] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118Valadez, AngelicaWelsh, MadeleineKim, ChristineJohns, AngelaAlgazi, AlainKang, HyunseokKang, Hyunseok
- [3] RAMUCIRUMAB IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS-CELL CARCINOMA: A PHASE 1-2 TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A385 - A385Adkins, DouglasLey, JessicaPalka, KevinJacobs, MiriamLiu, JingxiaOppelt, Peter
- [4] Phase 1/2 Study of Pepinemab in Combination with Pembrolizumab as First-Line Treatment of Advanced, Recurrent or Metastatic Head and Neck Cancer (KEYNOTE B84)INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E36 - E36Fisher, T. L.Evans, E. E.Mallow, C.Foster, A.Boise, M.Smith, E.Leonard, J. E.Chaney, M.Beck, J. T.Hager, S.Saba, N. F.Steuer, C.Adkins, D.Burtness, B.Zauderer, M.
- [5] Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trialNATURE MEDICINE, 2023, 29 (04) : 880 - 887Saba, Nabil F.Steuer, Conor E.Ekpenyong, AsariMcCook-Veal, AshleyMagliocca, KellyPatel, MihirSchmitt, Nicole C.Stokes, WilliamBates, James E.Rudra, SoumonRemick, JillMcDonald, MarkAbousaud, MarinTan, Aik ChoonFadlullah, Muhammad Zaki HidayatullahChaudhary, RituMuzaffar, JameelKirtane, KedarLiu, YuanChen, Georgia Z.Shin, Dong M.Teng, YongChung, Christine H.
- [6] REAL-WORLD USE OF PEMBROLIZUMAB COMBINATION REGIMENS IN FIRST-LINE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A832 - A832Black, ChristopherWang, LiyaRamakrishnan, KarthikGoto, Daisuke
- [7] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neckANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022Hitt, R.Irigoyen, A.Cortes-Funes, H.Grau, J. J.Garcia-Saenz, J. A.Cruz-Hernandez, J. J.
- [8] Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048ANNALS OF ONCOLOGY, 2015, 26 : 101 - 101Yen, C. J.Klochikhin, A.Cohen, E.Vermorken, J.Harrington, K.Tahara, M.Ge, Y.Geib, J.Jin, F.Burtness, B.
- [9] Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048ANNALS OF ONCOLOGY, 2015, 26 : 5 - 5Klochikhin, A.Greil, R.Cohen, E.Vermorken, J.Harrington, K.Tahara, M.Ge, J. Y.Geib, J.Jin, F.Burtness, B.
- [10] Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II studyANNALS OF ONCOLOGY, 2022, 33 (07) : S855 - S856Gui, L.He, X.Yang, J.Liu, P.Yan, Q.Shi, Y-K.